Insulin-producing cells injected into a man with type 1 diabetes have survived for a month so far without the need for immune ...

Recent advances in immunotherapy have revealed a promising frontier in Type 1 diabetes treatment: outsmarting rather than ...

Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Doctors don’t know exactly what causes type 1 diabetes. For some reason, the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. Genes may play a role in ...

Sana Biotechnology (SANA) announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic ...

“In type 1 diabetes, a person’s immune system attacks and destroys the beta cells. Today’s data, when combined with progress elsewhere in the field, provide real hope that a scalable, curative ...

The updated guidelines from the American Diabetes Association emphasize the use of antibody-based screening for type 1 ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...